Response to Letter to the Editor From Wagner et al: "An Unusually Prolonged Case of FGF23-Mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use".
作者信息
Arora Ipsa, Kaprove Alison, Perrone Ronald, Ceglia Lisa
机构信息
Division of Endocrinology, Tufts Medical Center, Boston, MA 02111, USA.
Division of Nephrology, Tufts Medical Center, Boston, MA 02111, USA.
出版信息
JCEM Case Rep. 2024 May 14;2(5):luae079. doi: 10.1210/jcemcr/luae079. eCollection 2024 May.
Abstract
摘要
相似文献
1
Response to Letter to the Editor From Wagner et al: "An Unusually Prolonged Case of FGF23-Mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use".
JCEM Case Rep. 2024 May 14;2(5):luae079. doi: 10.1210/jcemcr/luae079. eCollection 2024 May.
2
Letter to the Editor from Wagner et al: "An Unusually Prolonged Case of FGF23-Mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use".
JCEM Case Rep. 2024 May 14;2(5):luae078. doi: 10.1210/jcemcr/luae078. eCollection 2024 May.
3
An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use.
JCEM Case Rep. 2023 Sep 27;1(5):luad117. doi: 10.1210/jcemcr/luad117. eCollection 2023 Sep.
4
Randomized trial of intravenous iron-induced hypophosphatemia.
JCI Insight. 2018 Dec 6;3(23):124486. doi: 10.1172/jci.insight.124486.
5
Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series.
Transfus Med. 2023 Dec;33(6):503-508. doi: 10.1111/tme.12980. Epub 2023 Jun 1.
6
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
JAMA. 2020 Feb 4;323(5):432-443. doi: 10.1001/jama.2019.22450.
7
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Aliment Pharmacol Ther. 2019 Aug;50(4):397-406. doi: 10.1111/apt.15386. Epub 2019 Jul 2.
8
High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
Obes Surg. 2020 Jul;30(7):2659-2666. doi: 10.1007/s11695-020-04544-x.
9
Refractory hypophosphatemia following ferric carboxymaltose administration.
CEN Case Rep. 2021 Nov;10(4):473-475. doi: 10.1007/s13730-021-00590-1. Epub 2021 Mar 14.
10
Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
BMC Med. 2020 Jul 13;18(1):178. doi: 10.1186/s12916-020-01643-5.
本文引用的文献
1
An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use.
JCEM Case Rep. 2023 Sep 27;1(5):luad117. doi: 10.1210/jcemcr/luad117. eCollection 2023 Sep.
2
Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation.
Bone Rep. 2023 Jan 11;18:101655. doi: 10.1016/j.bonr.2023.101655. eCollection 2023 Jun.
3
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.
Kidney360. 2020 Jul;1(7):648-656. doi: 10.34067/KID.0001692020. Epub 2020 Jul 30.
4
A distinct bone phenotype in ADPKD patients with end-stage renal disease.
Kidney Int. 2019 Feb;95(2):412-419. doi: 10.1016/j.kint.2018.09.018.
5
Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Kidney Int. 2014 Jun;85(6):1340-50. doi: 10.1038/ki.2013.526. Epub 2014 Jan 8.
6
Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
J Bone Miner Res. 2013 Aug;28(8):1793-803. doi: 10.1002/jbmr.1923.
Zotero 插件